院前使用糖皮质激素与缺血性卒中患者心血管事件风险
基于丹麦全国登记数据的队列研究纳入98487例首次缺血性卒中患者,按糖皮质激素使用状态分组。当前使用与心肌梗死和静脉血栓栓塞风险轻度升高相关,出血性卒中风险降低,复发性缺血性卒中风险无关联。
要点
- 当前使用糖皮质激素者1年复发性缺血性卒中累积发生率为16.4%。
- 当前使用糖皮质激素者心肌梗死aHR为1.32(95%CI 0.98-1.76),静脉血栓栓塞aHR为1.39(95%CI 0.99-1.94)。
- 当前使用糖皮质激素者出血性卒中风险降低(aHR 0.60,95%CI 0.38-0.93)。
核心结论
- 缺血性卒中后第一年内,当前使用糖皮质激素与心肌梗死和静脉血栓栓塞风险轻度升高相关,与出血性卒中风险降低相关,而复发性缺血性卒中风险未受影响。
研究设计与样本
- 基于丹麦全国医学登记数据的全国性人群队列研究,纳入2004年至2013年间所有首次缺血性卒中住院患者,共98487例。
- 糖皮质激素使用分为当前使用(入院前90天内最后一次处方取药)、既往使用和未使用,以未使用者为参照。
- 采用Cox回归分析计算合并症和合并用药校正的1年风险比(aHR)及95%置信区间(CI)。
主要发现
- 当前使用糖皮质激素者卒中后1年复发性缺血性卒中累积发生率为16.4%,出血性卒中为0.46%,心肌梗死为1.35%,静脉血栓栓塞为0.98%。
- 当前使用糖皮质激素者心肌梗死aHR为1.32(95%CI 0.98-1.76),静脉血栓栓塞aHR为1.39(95%CI 0.99-1.94)。
- 当前使用糖皮质激素者出血性卒中风险降低(aHR 0.60,95%CI 0.38-0.93)。
- 当前使用糖皮质激素与复发性缺血性卒中无关联(aHR 1.01,95%CI 0.94-1.09)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials The risk of thrombosis among ischemic stroke patients using glucocorticoids is unknown. We examined the risk of thrombosis in 98 487 ischemic stroke patients, by glucocorticoid use. Myocardial infarction and venous thromboembolism risk was increased in glucocorticoid users. Hemorrhagic stroke risk was lower and recurrent ischemic stroke the same in glucocorticoid users. SUMMARY: Background Glucocorticoid users have a high mortality rate following stroke, but the underlying clinical pathways are poorly understood. Objectives To examine the risk of cardiovascular events among ischemic stroke patients using glucocorticoids. Methods We conducted a nationwide population-based cohort study by using medical registries in Denmark. We identified all patients hospitalized with a first-time ischemic stroke (2004-2013). We categorized glucocorticoid use into current use (last prescription redemption ≤ 90 days before admission), former use, and non-use. With non-users as reference, we studied the risks of recurrent ischemic stroke, hemorrhagic stroke, myocardial infarction and venous thromboembolism associated with glucocorticoid use. Comorbidity and comedication-adjusted 1-year hazard ratios (aHRs) with 95% confidence intervals (CIs) were computed on the basis of Cox regression analysis. Results We identified 98 487 patients with a first-time (index) ischemic stroke. After the index stroke, the 1-year cumulative incidence of recurrent ischemic stroke was 16.4% among current glucocorticoid users, whereas risks were lower for hemorrhagic stroke (0.46%), myocardial infarction (1.35%), and venous thromboembolism (0.98%). Among current glucocorticoid users, aHRs were increased for myocardial infarction (1.32, 95% CI 0.98-1.76) and venous thromboembolism (1.39, 95% CI 0.99-1.94), whereas the risk of hemorrhagic stroke was reduced (aHR 0.60, 95% CI 0.38-0.93). There was no association with recurrent ischemic stroke (aHR 1.01, 95% CI 0.94-1.09). Conclusions During the first year after ischemic stroke, current glucocorticoid use was associated with moderately increased risks of myocardial infarction and venous thromboembolism, and a lower risk of hemorrhagic stroke, whereas the risk of recurrent ischemic stroke was not affected.
引用
- Sundbøll J, Darvalics B, Horváth-Puhó E, et al. Preadmission use of glucocorticoids and risk of cardiovascular events in patients with ischemic stroke. J Thromb Haemost. 2018. PMID: 30179297. doi:10.1111/jth.14283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。